DCIS, or ductal carcinoma in situ, is the earliest possible form of breast cancer. It means that cells lining the milk ducts of the breast have become cancerous, but they haven’t broken through the duct wall or spread anywhere else in the body. That “in situ” part of the name literally means “in place.” Because the abnormal cells stay contained, DCIS is classified as stage 0 and is non-invasive. Ten-year survival rates sit above 98% regardless of treatment approach, but DCIS still requires careful decisions because an estimated 20 to 50 percent of untreated cases could eventually progress to invasive breast cancer.
How DCIS Is Found
Most people with DCIS have no symptoms at all. The condition is almost always caught on a routine screening mammogram, where it shows up as tiny calcium deposits called microcalcifications. Not all calcifications signal a problem. Large, round, well-defined calcium spots are typically benign. What raises concern is a tight cluster of tiny, irregularly shaped calcifications, which can indicate DCIS.
If a screening mammogram picks up a suspicious cluster, you’ll usually be called back for a diagnostic mammogram. This version takes images at higher magnification and from more angles. An ultrasound may follow, and if the area still looks concerning, a biopsy confirms or rules out DCIS. During a core needle biopsy, a hollow needle removes a small tissue sample for lab analysis. The needle is guided by either ultrasound or X-ray imaging (called a stereotactic biopsy), depending on what works best for the location of the calcifications.
Low Grade vs. High Grade DCIS
Once a biopsy confirms DCIS, a pathologist grades it based on how abnormal the cells look under a microscope. This grade matters because it influences both the risk of progression and the treatment plan.
Low-grade DCIS cells look relatively close to normal. They tend to form orderly patterns and grow slowly. These cells almost always have estrogen receptors on their surface, which means hormonal therapies can be effective against them. High-grade DCIS looks very different: large, irregularly shaped cells with areas of dead tissue (necrosis) inside the ducts. High-grade DCIS is more likely to overexpress a growth-promoting protein called HER2. Intermediate-grade DCIS falls between the two. Research has shown that low-grade and high-grade DCIS are genetically distinct, not just different points on the same spectrum. This is one reason treatment decisions aren’t one-size-fits-all.
Treatment Options
The standard treatments for DCIS are surgery, sometimes followed by radiation, and in certain cases hormone therapy. Because DCIS hasn’t spread, the goal of treatment is preventing it from ever becoming invasive cancer.
Lumpectomy
Breast-conserving surgery, or lumpectomy, removes the area of DCIS along with a margin of surrounding healthy tissue. Surgeons aim for at least a 2-millimeter clear margin around the removed tissue, which studies show improves recurrence outcomes. A lumpectomy preserves the rest of the breast.
Mastectomy
Removing the entire breast is less common for DCIS but may be recommended when DCIS is widespread across a large area, when clear margins can’t be achieved with lumpectomy, or when a patient prefers it for peace of mind. Recurrence rates after mastectomy for DCIS are very low, around 3.4% in one large study.
Radiation After Lumpectomy
Radiation therapy after lumpectomy significantly lowers the chance of DCIS returning in the same breast. In a study tracked over 12 years at Memorial Sloan Kettering, only 2.8% of women who received radiation after surgery had a local recurrence, compared to 11.4% of women who had surgery alone. Despite this fourfold difference in recurrence, radiation does not change overall survival rates, which remain above 98% either way. That means the decision to add radiation often comes down to balancing the side effects and time commitment of treatment against the reduced risk of needing a second surgery later.
Hormone Therapy
For DCIS that tests positive for hormone receptors (which is especially common in low-grade cases), hormone-blocking medication can further reduce the risk of recurrence. One trial showed a 42% reduction in breast cancer events and a 64% reduction in cancer developing in the opposite breast with a low dose of tamoxifen. Another class of drugs called aromatase inhibitors has shown results that are at least as good as tamoxifen, and possibly better for women under 60. It’s worth noting that hormone therapy for DCIS reduces recurrence risk but does not improve survival, since survival is already so high.
Active Surveillance: Watching Instead of Operating
One of the biggest questions in breast cancer care right now is whether all DCIS needs to be surgically removed. A major clinical trial called COMET, published in late 2024, enrolled 957 women with low-risk DCIS and randomly assigned them to either standard surgery or active monitoring without immediate surgery.
Women in the monitoring group received diagnostic mammograms every six months on the affected breast and yearly on the other breast, plus regular physical exams. If imaging showed changes like a new mass, new distortion, or calcifications growing by 5 millimeters or more, a biopsy was recommended. Surgery was only required if the biopsy found invasive cancer. If the biopsy still showed only DCIS, continued monitoring was the recommendation. Women could also choose surgery at any point if they preferred.
This approach reflects a growing recognition that some DCIS may never become dangerous in a person’s lifetime, and that treating every case with surgery might mean overtreating patients who would never have had a problem. Active surveillance is not yet standard practice, but trials like COMET are building the evidence base that could change guidelines in the coming years.
Recurrence and Long-Term Outlook
The prognosis for DCIS is excellent by any measure. Ten-year breast cancer survival is 98.9% for women treated with lumpectomy plus radiation, 98.5% for mastectomy, and 98.4% for lumpectomy alone. These numbers are remarkably close to each other, which is why treatment decisions often focus on quality of life and personal preference rather than survival differences.
When DCIS does recur, about half the time it comes back as DCIS again, and about half the time it returns as invasive cancer. High-grade DCIS, DCIS with close or positive surgical margins, and younger age at diagnosis are all associated with a higher recurrence risk. This is why follow-up care after treatment typically includes regular mammograms and clinical breast exams for years afterward.
The challenge with DCIS has never been that it’s immediately dangerous. It’s that doctors can’t yet reliably predict which cases will stay harmless and which will eventually turn invasive. Until that distinction becomes clearer, treatment decisions involve weighing a very good prognosis against the uncertainty of doing less.